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ABSTRACT

A CANCER-TARGETED GOLD NANOPARTICLE-BASED MRI CONTRAST
AGENT

Nagwa El-Baz
July 5, 2018

In oncology, imaging plays a major role in terms of early detection and treatment
of most types of cancer. Magnetic resonance imaging (MRI) is mostly used for cancer
diagnosis due to its excellent contrast resolution. However, MRI for cancer diagnosis is
somewhat limited by its sensitivity. In this thesis, we assessed the ability of theranostic
platform consisting of gold nanoparticles functionalized with a cancer targeting aptamer;
AS1411 and gadolinium chelate (Dotarem thiol derivative; Gd (III)-DO3A) as a MRI
contrast agent to target malignant tumors by enhancing the MRI contrast of the detected
tumor. The proposed technology is a novel injectable contrast agent for detection and
monitoring of malignancies by MRI. The gold nanoparticle core (GNPs) enhances the
pharmacokinetic properties of the proposed contrast agent, increases its potency, and
provides a good way to co-localize the aptamer with the contrast agent. AS1411 is antinucleolin aptamer that binds to nucleolin protein, which is highly expressed in cancer cells,
leading to selective accumulation in cancers cells. The ability of the proposed contrast
agent to target cancer cells and enhance MRI contrast was assessed using MDA-MB-231
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triple negative breast cells and MCF-10 human mammary epithelial cells. Moreover we
assessed the biodistribution and toxicity of the proposed contrast agent in vivo.
The results presented in this thesis demonstrate the superiority of the proposed
contrast agent with respect to the current commercial contrast agents (e.g., MultiHance).
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CHAPTER 1. INTRODUCTION

1.1. Current Technology for Cancer Diagnosis:
Cancer is a major public health problem worldwide and the second leading cause
of death in the United States [1]. Cancer is a group of diseases that can be characterized by
uncontrolled growth of abnormal cells. If the cell growth is not controlled, it can result in
metastasis of the cancer, and eventually, death. In 2018, about 1.7 million new cancer cases
are expected to be diagnosed [2]. Moreover, about 609,640 Americans are expected to die
of cancer in 2018 (see Figure 1) [2]. As reported by the American Cancer Society, in 2015,
the cancer mortality rate had dropped 26% from its peak in 1991. This decline translated
into about 2.4 million deaths avoided during this time period [2]. One of the main reasons
for this drop is the improvement in early detection and treatment of most types of cancer.
Nowadays, medical imaging plays an important role in diagnosis, staging, monitoring
therapeutic response, and treatment planning for almost all cancer types. Each year in USA,
more than 71 million Computed Tomography (CT) and 33 million Magnetic Resonance
Imaging (MRI) scans are performed for the purpose of detection of primary or metastatic
malignant tumors [3]. CT, MRI, and Positron Emission Tomography (PET) are the three
major imaging modalities in clinical radiology that are used in cancer diagnosis and
treatment.
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CT scans combine a series of X-ray images which are taken from different angles
and uses computer processing to create cross-sectional images of the interested body organ.
CT is the most commonly used modality because it is fast and has widespread availability.
CT images provide high resolution of the organ of interest, which can be used to extract all
the anatomical features of any detected tumors. Unfortunately, the sensitivity and
specificity of diagnosing malignant tumors based only on the anatomical features are low,
which makes it unacceptable in the clinical setting. Moreover, some CT intravenous
contrast agents are contraindicated with some patients with renal problems. Finally, CT has
a limited ability in detected the tumors that may exist in the soft tissues (e.g., brain, liver,
etc.)

Figure 1: Estimated Numbers of Cancer Cases for 2018 in the USA, excluding basal
cell and squamous cell skin cancers and in situ carcinomas except urinary bladder [2].
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MRI, also known as nuclear magnetic resonance imaging, is a scanning technique
for creating three dimensional detailed images of the regions of interest. To perform an
MRI scan, the person is positioned within an MRI scanner that forms a strong magnetic
field (that forces the magnetic moment of protons in the body tissues to be aligned with the
magnetic field). Then, a radiofrequency pulse is applied which disrupts the protons and
forces them to rotate 90 or 180 degrees against the pull of magnetic field. When the
radiofrequency pulse is turned off the protons rotate to realign again with the magnetic
field, releasing electromagnetic energy. MRI scanners detect the released electromagnetic
energy as well the time taken for protons to relax or realign with the magnetic field. These
two factors are different depending on the environment of the protons. Technicians can
differentiate between different body tissues based on these factors. T1-weighted (spinlattice) and T2-weighted (spin-spin) are the basic two MRI image types. A T1-weighted
image is useful for assessing the cerebral cortex, identifying fatty tissue, characterizing
focal liver lesions and in general for obtaining morphological and anatomical information,
as well as for post-contrast imaging. A T2-weighted image is useful for detecting edema
and inflammation, revealing white matter lesions and assessing zonal anatomy in the
prostate and uterus. The main advantage of MRI scans is its ability to detect tumors/lesions
in the soft tissues at an early stage [4]. However, MRI sensitivity and specificity for
diagnosing malignant tumors is low.
PET is a nuclear medicine functional imaging technique that is used to observe
metabolic processes in the body. PET is both a clinical and research tool. PET relies on
cancer-selective uptake of radiolabeled sugars and provides better information for
malignant status for some (but not all) tumor types; however, its use is limited by its
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expense and the necessity for short-lived radiopharmaceuticals that require a synchrotron
source. Also, its sensitivity and resolution for diagnosing tumors is low compared with CT
and MRI. On the other hand, the main advantage of PET is it has high specificity of tumor
diagnosis.

1.2. Current Imaging Contrast Agents:
In most cases before applying MRI and CT scans intravenous contrast agents are
administered. Contrast agents are chemical materials that improve visualization of tissues
and body organs. For CT, all contrast agents are iodine-based reagents that absorb and
diffract X-rays. There are 13 different CT contrast agents that are FDA-approved. There
have been no novel CT contrast agents approved since 1997 [5]. Iodine contrast agents
have mild and self-limiting adverse effects in healthy individuals but individuals with
impaired renal function can have severe and serious adverse effects including anaphylaxis
and nephropathy. Moreover iodine-based contrast agents have short half-lives and rapid
clearance, and therefore may require multiple injections [6].
For MRI, most common contrast agents are gadolinium-based (11 types are FDAapproved). Gadolinium ions are paramagnetic and shorten the relaxation time of the excited
protons in body tissues and enhance changes in signals between adjacent tissues, which
may depend on tissue type or blood flow. Like CT contrast agents, MRI contrast agents are
generally safe for all patients except patients with impaired renal function. These contrast
agents may develop nephrogenic systemic fibrosis (7).
The existing contrast agents for CT and MRI are effective at enhancing anatomical
imaging, but they are not cancer-specific and largely fail to distinguish malignant from
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benign lesions. That is why there is an urgent need to develop cancer-targeted contrast
agents to diagnose cancer at an early stage. The Molecular Imaging and Contrast Agent
Database (MICAD) lists more than 5,000 targeting compounds that have been reported in
the literature with around 2,000 for cancer diagnosis. Many cancer-targeted ligands have
been tested, such as peptides, antibodies, small molecules, and aptamers. Aptamers have
numerous advantages due to ease of synthesis, their nano-size, physical properties, and
versatile chemistry.

1.3. Anti-Nucleolin Aptamer AS1411:
AS1411 is a quartet G-rich oligodeoxynucleotide that specifically binds to a
phosphoprotein called nucleolin that is overexpressed in almost all cancer cells where it is
found on the cell surface and in the cytoplasm. Nucleolin is absent from the cell surface
and cytoplasm of almost all normal cells. AS1411 has apoptotic induction activity through
binding to nucleolin, which inhibits nucleolin binding to BCL2 mRNA (BCL2 is a family
of regulatory proteins that regulate cell apoptosis by either inducing or inhibiting
apoptosis). AS1411 is taken up in cancer cells by macropinocytosis, which leads to specific
accumulation in cancer cells. The majority of targeted agents in MICAD database are
peptides or antibodies, which target specific molecular targets that are expressed in small
subset of cancers, whereas AS1411 has a near-universal cancer targeting mechanism
because nucleolin is expressed in most cancer types. AS1411 is the first aptamer to be
tested in human trials, and it passed phase I and II clinical trials. More than 100 patients
were treated with no serious adverse events reported. Moreover, there is some evidence of
clinical benefit. However, the response was low due to poor pharmacokinetics (rapid
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clearance from the body and serum concentration is not enough to kill most cancer cells)
and low potency of AS1411.

1.4. Conjugation of AS1411 with Gold Nanoparticles (GNPs):
Gold nanoparticles (GNPs) are extensively employed as therapeutic and diagnostic
platforms in biotechnology-based applications. GNPs have unique dimensions, tunable
functionalities on the surface and display controllable drug release. While traditionally,
GNPs have been functionalized with therapeutic agents, disease targeting agents or
diagnostic/ contrast agents, recent efforts have focused on combining disease targeting,
diagnostic technologies and therapeutics into a single theranostic agent.
In this thesis, we propose a theranostic construct using GNPs conjugated with
AS1411 (cancer targeting therapeutic aptamer) and gadolinium chelate (Dotarem thiol
derivative; Gd (III)-DO3A) as MRI contrast agents [10] (see Figure 2). Conjugation of
AS1411 with GNPs has many advantages over using AS1411 alone. AS1411-GNPs have
a dramatic increase in uptake by cancer cells (along with up to 50-fold increase in potency
against cancer cells) while maintaining cancer selectivity (no effect on normal cells) and
display antitumor activity in mice with no evidence of toxicity [9]. Additionally, AS1411
can be easily co-localized to GNPs using a thiol group.

6

Figure 2: GNP functionalized with Gd (lll) DO3A-SH and AS1411.

Gd (III) ions cannot be administered directly in their ionic form because they are
very toxic. Gd (III) ions interfere with calcium channel and protein binding sites, and also
accumulate in liver, bones, spleen, and kidney. That is why Gd(III) ions are formulated
with chelating agents to prevent tissue interaction and minimize their toxic effect [11] (see
Figure 3). Here we use DO3A (1,4,7,10-tetraazacyclododecane-N,N',N″,N‴-tetraacetic
acid) as chelating agent with a thiol group that allows conjugation of Dotarem to GNPs.
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Figure 3: Gd ion is chelating to DO3A with thiol group.

The first goal of this study is to investigate the ability of the proposed contrast agent
to enhance the contrast of MRI images using MDA-MB-231 triple negative breast cells
line and MCF-10 human mammary epithelial cells line. The second goal is to evaluate the
biodistribution and the potential toxicity of the proposed contrast agent in vivo.
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CHAPTER 2: MATERIALS AND METHODS

2.1. Chemicals and Materials:
HAuCl4·3H2O was purchased from Alfa Aesar (Tewksbury, MA). Citric acid,
trisodium salt (Na3C6H5O7), Sodium Borohydride (NaBH4), Gadolinium trichloride
hexahydrate (GdCl3·6H2O), dithiothreitol (DTT) and anhydrous sodium bicarbonate
(NaHCO3) were purchased from Sigma Aldrich (St. Louis, MO). 10X PBS (pH 7.4) and
OliGreen dye were purchased from Thermo Fisher Scientific (Waltham, MA). Nanopure
ultrapure water (Barnstead, resistivity of 18.2 MΩ-cm) was used for preparing all aqueous
solutions. Analytical grade hydrochloric acid (HCl) and nitric acid (HNO3) were purchased
from VWR (Rednor,PA). Aqua Regia solution (3 parts HCl and 1 part HNO3) was used to
clean all glassware for GNP synthesis. The tetraazamacrocycle 10-(2-sulfanylethyl)1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (H4DO3ASH) was purchased from
Macrocyclics, Inc. (Dallas, TX). Oligonucleotides having a regular DNA backbone
(phosphodiester), a 5’-Thiol C6 S-S modification (Thio-MC6-D), 5’-6T spacer (for
AS1411 and CRO) and high pressure liquid chromatography (HPLC) purification were
supplied by Integrated DNA Technologies (IDT) [Coralville, IA].
The oligonucleotides sequences used were:
5’TTTTTTGGTGGTGGTGGTTGTGGTGGTGGTGGTTT (AS1411),
5’-TTTTTTCCTCCTCCTCCTTCTCCTCCTCCTCCTTT (CRO)
9

and TTTTTT (CTR).
MDA-MB-231 breast cancer cells and MCF-10A healthy mammary gland cells were
purchased from ATCC (Manassas, VA). MEBM media with Bullet Kit Media were
purchased from Lonza Group (Basel, Switzerland). DMEM, Fetal Bovine Serum (FBS),
10X Trypsin, Penicillin/Streptomycin (Pen/Strep) & Gentamicin were all purchased from
Thermo Fisher Scientific (Waltham, MA). Phosphate-buffered saline (PBS) 1X without
calcium or magnesium was purchased from Gibco. Accutase solution was purchased from
Sigma-Aldrich. (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), MTT
reagent was purchased from Sigma (Cream Ridge, NJ). Sodium dodecyl sulfate (SDS) was
purchased from Thermo Fisher Scientific. Tissue culture flasks, dishes and plates were
purchased from Thermo Fisher Scientific. Amicon Ultra 15.0 ml centrifugal filters with
Ultracel-30 (30000 MWCO) were purchased from Merck Millipore (Billerica, MA) to
remove excess oligonucleotide and Gd(III)-DO3A-SH. The 0.6 ml Eppendorf
microcentrifuge tubes were purchased from Sigma Aldrich (St. Louis, MO) to mount
samples at 9.4 T (Agilent) MRI scanner.
UV absorption spectra were measured with a UV Visible Spectrometer (Varian
Cary 50 BIO UV, Agilent Technologies, Santa Clara, CA). Dynamic Light Scattering
measurements (DLS) were acquired on a Zetasizer (Zetasizer Nano ZS90, Malvern
Instruments Ltd., Westborough, MA). The Zeta potential measurements were acquired
using a NanoBrook Zeta PALS Zeta Potential Analyzer (Brookhaven Instruments,
Holtsville, NY). Tunneling electron microscopy (TEM) studies was performed on the FEI
Tecnai F20 TEM to determine GNP morphology and distribution. Fluorescence studies
were performed on the enhanced darkfield Cytoviva fluorescence microscope (CytoViva,
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Inc., Auburn, AL).
2.2. Chemical synthesis of 4 nm GNPs:
Gold nanoparticles were synthesized according to the procedure described by
Murphy and coworkers [12]. A 2.5 mL of 0.01M citric acid, trisodium salt was added to
95.0 mL of nanopure water under intense stirring. Then, 2.5 mL of 0.01M HAuCl4 solution
was added followed immediately by 3.0 mL of 4ºC 0.1M sodium borohydride. The solution
was stirred for 2 hours. GNPs size was determined by UV/vis and dynamic light scattering.

2.3. Chemical Synthesis of Gadolinium (III) DO3A-SH:
The tetraazamacrocycle 10-(2-sulfanylethyl)-1,4,7,10-tetraaza cyclododecane1,4,7-triacetic acid (DO3ASH) was chelated with GdCl3 by mixing an aqueous solution of
DO3A-SH (15.8 µmol, 100 μl) with an aqueous solution of GdCl3 (347 mM, 50 µL) at
room temperature [13-15] The reaction mixture pH was then adjusted to 6.0 with 1.0 M
sodium bicarbonate and the mixture incubated overnight at 60ºC. During the reaction, the
pH was monitored three times and bicarbonate solution added as necessary to keep the pH
in the range of 6-7. Afterwards, the reaction mixture pH was adjusted to 9-10 using sodium
bicarbonate and then centrifuged at 3000 g for 15 minutes. The sample was then vacuum
filtered and the precipitate air-dried.

2.4. Preparation of AS1411/CRO/CTR for conjugation to GNP:
Oligonucleotides having a regular DNA backbone (phosphodiester), a 5’-Thiol C6
S-S modification (Thio-MC6-D), and high pressure liquid chromatography (HPLC)
purified were supplied by Integrated DNA Technologies (IDT). Oligonucleotide solutions
were prepared as previously reported [16]. Briefly, 500 µl of 500 µM oligonucleotide
11

solution was prepared by suspending AS1411/CRO/CTR in nanopure water. Prior to use,
the disulfide protecting group on the oligonucleotide solution was cleaved with
dithiothreitol (DTT). A 250 µl solution of 1M DTT was added to 60 µl of 500 µM
oligonucleotide solution and heated at 90°C for 1 hour (0.1 M DTT, 0.18 M phosphate
buffer (PB), pH 8.0). The cleaved oligonucleotides were purified using a NAP-5 column
eluted with PB. Thereafter, the eluted solution of freshly cleaved oligonucleotides was
added to gold nanoparticle dispersions.

2.5. Chemical synthesis of GNP–Gd(III)-DO3A-SH- Oligonucleotide:
Gold nanoparticles (GNP) were functionalized with the MRI contrast agent Gd(III)DO3A-SH and/or thiol-deprotected oligonucleotide (AS1411/CRO/CTR). The freshly
cleaved oligonucleotide solution was added to the GNP dispersion (~170 nM) [12] to bring
the mixture to 1.2 µM oligonucleotide concentration [16] while simultaneously adding
Gd(III)-DO3A-SH to achieve 1.3 mM contrast agent concentration. The GNPGd(III)DO3A-SH-Oligonucleotide solution was incubated at room temperature for 20
minutes and then sonicated for 10 minutes. The solution was incubated overnight at 37ºC.
The concentration of NaCl was gradually increased to 137 mM using 10X PBS over 3 days.
During each salt addition, the GNP-Gd(III)-DO3A-SH-Oligonucleotide solution was
sonicated for 60s followed by incubation at 37ºC. As mentioned, the excess oligonucleotide
and Gd(III)-DO3A-SH were removed via centrifugal filtration at 3000g for 30 min. The
concentrated solution was re-suspended to 15.0 ml with 1.0 X PBS and filtered two more
times before use.
2.6. Oligonucleotides Quantification:
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45.0 μl of the centrifuged pellets of GNP-Gd(III)DO3A-SH-Oligonucleotide were
redispersed to 2.0 ml samples at 45X dilution in GNP stripping solution (5 μL of 1.0 M
DTT, 0.1M phosphate buffer (pH 8)) and incubated overnight at 37 °C to cleave the gold
oligonucleotide-thiol bond. Within 24 hours, after the gold nanoparticles precipitate, the
supernatant was collected and the released oligonucleotides were quantified using UV
absorption spectra.

2.7. Transmission Electron Microscopy:
Transmission electron microscopy (TEM) images were obtained using a FEI Tecnai
F20 TEM. A field emission gun (FEG) was used for the electron source and the studies
were performed with an accelerating voltage of 360 keV. The samples were prepared by
suspending 20.0 μl of 0.5-0.6 μM concentration of GNP samples onto a C-flat holey carbon
film mesh on copper grids and air dried overnight. The size histogram analysis of the TEM
images was performed with ImageJ software.

2.8. Fluorescence:
The samples (the synthesized GNPS) were tagged with the fluorescent dye
OliGreen™ using the protocol provided by the manufacturer. Excess dye was removed
through centrifugation at 3000 rpm for 30 min. A Modulus Fluorimeter (Promega,
Madison, WI) was used to measure the fluorescence of the samples (Blue module: Ex 460
nm, Em: 518-570 nm). The samples were also imaged with an enhanced darkfield
(Cytoviva) fluorescence microscope. The samples were prepared by drop casting 10.0 μL
of sample onto a glass microscope slide (Fisherbrand Superfrost Plus) and then placing a
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coverslip overtop (VWR micro cover glass). Lacquer (Nail Polish) was then used to create
a waterproof seal around the edges. The samples were imaged at 60x magnification.

2.9. Gadolinium quantification with Energy Dispersive X-Ray Analysis:
Energy Dispersive X-ray Analysis (EDAX) was performed on a Zeiss SUPRA 35
FE-SEM (Zeiss Peabody, MA) at 20 KeV incident beam at 8.1 mm working distance. The
atomic ratios of Gd:Au were measured for GNP –Gd(III)-DO3A-SH- oligonucleotide to
quantify Gd content per GNP.

2.10. Cell Culture development:
MDA-MB-231 and MCF-10A cells were maintain DMEM and MEBM,
respectively. Cells were cultured in a 5% CO2 incubator at 37°C and media were replaced
with fresh media every two to three days. Cells were subcultured every four to five days
using PBS for MDA-MB-231 and accutase for MCF-10A.

2.11. MRI Agarose Phantoms:
Samples for MRI imaging were prepared by mixing different concentrations (1200,
300 and 75 nM) of gold nanoparticles functionalized with Gd(III)- DO3A-SH and
oligonucleotide (AS1411/CRO/CTR) with agarose solution (0.7%, 55°C) in 1:1 ratio in 0.5
mL Eppendorf microcentrifuge tubes. The uniform dispersions were allowed to stand at
room temperature for 30 minutes to solidify. Samples were mounted on a mesh grid and
MRI images were acquired on the 9.4 T instrument (Agilent) for T1 W and T1 MRI
measurements. Concentrations of gold nanoparticles (1200 nM, 300 nM and 75 nM)
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functionalized with Gd(III)- DO3A-SH and oligonucleotide (AS1411/CRO/CTR) were
diluted in agarose solution (0.7%) and mounted on the 9.4 T instrument holder for their T1
W and T1 MRI measurements.

2.12. MR imaging:
All MR imaging data were acquired using Agilent 9.4 T horizontal bore MRI
system equipped with Agilent 205/120 HD gradient coil (Agilent Technologies, Santa
Clara, CA, USA). A RAPID 72-mm volume coil was used for signal transmission and
detection (RAPID MR International, Columbus, OH, USA). After a quick 3-plane gradient
echo-based scout scan to verify sample positioning, T1-Weighted images were obtained
using a standard spin echo multi-slice (SEMS) imaging sequence with the following
parameters: TR/TE = 500/10 msec; matrix size = 128 x 128; field of view (FOV) = 40 x
40 mm2; 13 slices with a slice thickness of 1.0 mm. When acquiring data for T1 calculation
purposes, a fast spin echo multi-slice (fSEMS) sequence was used with the following
parameters: TR (array) = 6000, 4700, 3600, 2800, 2200, 1700, 1300, 1000, 800 msec;
effective TE = 20 msec; matrix size = 128 x 128; field of view (FOV) = 40 x 40 mm 2; 9
slices with a slice thickness of 2.0 mm and 2 averages. All data from 9.4T MRI system
were converted to DICOM format using VNMRJ 4.0 interface before transferring to other
software for further data processing. Samples were also scanned using a 3 T Siemens
MAGNETOM Skyra (Siemens Medical Solutions, Malvern, PA, USA) with a 20 channel
head coil. A turbo spin echo (TSE) sequence was used under 3 T for T1 quantification: TR
(array) = 5000, 2000, 1000, 750, 500 msec; TE = 10 msec; matrix size = 256 x 256; field
of view (FOV) = 18 x 18 cm2; 17 slices with a slice thickness of 1.4 mm.
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2.13. Determination of GNP –Gd(III)-DO3A-SH- Oligonucleotide cellular uptake using
live MDA-MB-231 and MCF-10A:
MDA-MB-231and MCF-10A were treated with different concentrations of gold
nanoparticles (1200 nM, 300 nM, and 75 nM) functionalized with Gd(III)-DO3A-SH and
AS1411/CRO/CTR made in complete DMEM and MEBM, respectively, and incubated for
24, 48, 72 & 96 hour time points at 37°C to allow cell uptake and localization. After the
prescribed incubation time, the media was discarded and cells were washed 3 times with
1X PBS to remove any excess and unbound gold nanoparticles that were not internalized
within the cells. Cells were detached from the monolayer using TryPLE and accutase
solutions for 5 minutes at 37°C, transferred to a 15 mL conical tube, and centrifuged at 700
rpm to pellet the cells and separate any remaining unbound gold nanoparticles. Excess gold
nanoparticles, TryPLE, and accutase solutions were removed and cell pellets were
suspended in 100 l of 1X PBS, and transferred to 0.5 mL tubes with the addition of 100.0
µl of 1.4% agarose to give a final concentration of 0.7% agarose for a clear homogenous
solution. Cells were then mounted on the 9.4 T instrument mesh grid holder for T1Weighted and T1 MRI measurements.

2.14 T1-Weighted image analysis algorithm:
The T1-Weighted image calculation algorithm starts with single-click selection of
the two Eppendorf microcentrifuge tubes (0.5 ml) to be analyzed (see Fig. S5 (a)). Then a
background removal and a 3D region-growing algorithm is applied to extract the volume
of interest (VOI) that contains each microcentrifuge tube (0.5 ml) in the middle of the VOI
(see Fig.S5 (b-f)). The second step is to perform a two-step 3D registration technique to
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guarantee a voxel-on-voxel match between sample and control for accurate relaxivity
calculations. The registration technique begins with a global alignment using a 3D affine
transformation model. In order to perform the global registration, the distance maps inside
the reference and target microcentrifuge tubes (0.5 ml) are generated by finding the
minimum Euclidean distance for every inner voxel to the object boundary using a fast
marching level set. Then a 3D affine transformation with 12 degrees of freedom is applied
to align the target microcentrifuge tube (0.5 ml) to the reference one by maximizing the
mutual information of the generated distance maps. The second registration step is to
perform a non-rigid alignment (a step confirming voxel on voxel match) using a
multiresolution elastic registration approach which is based on 3D cubic B-splines with
four-stage multiresolution and using limited memory Broyden-Fletcher-Goldfarb-Shanno
(L-BFGS-B) optimization [19].
The traditional method to calculate the relaxivity is as follows:
𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑅𝑒𝑙𝑎𝑥𝑖𝑣𝑖𝑡𝑦 (𝑅) =

(𝑇𝑒𝑠𝑡)𝑎𝑣𝑟 −(𝐶𝑜𝑛𝑡𝑟𝑜𝑙)𝑎𝑣𝑟
(𝐶𝑜𝑛𝑡𝑟𝑜𝑙)𝑎𝑣𝑟

∗ 100

(1)

Since after aligning the MRI data, we have voxel-on-voxel match, then the proposed
equation to calculate the relaxivity is as follows:
∑𝑁
𝑖=1(𝐼𝑖 )𝑡𝑒𝑠𝑡 − (𝑔𝑖 )𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑅𝑒𝑙𝑎𝑥𝑖𝑣𝑖𝑡𝑦 (𝑅) =
× 100
∑𝑁
𝑖=1(𝑔𝑖 )𝑐𝑜𝑛𝑡𝑟𝑜𝑙

(2)

Where N is the number of voxels in each image, Ii is the MRI signal of the test cells and gi
is the MRI signal of control cells as demonstrated in Figure 4.
Note that each MR scan has one microcentrifuge tube (0.5 ml) filled with water. All our
data from any MRI scan is divided by the average signal of water. Finally, after calculating
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the relaxivity using Eq. 2, the proposed approach generates the color map that shows the
relaxivity of each voxel as shown in Figure 5.

(a) Test

(b) control

Figure 4: Illustration of the proposed relaxivity calculation.

Figure 5: An illustration of color map generated of relaxivity
enhancement. Red color means 100% improvement in the relaxivity as demonstrated in
the color coded bar.

2.15. In vivo Biodistribution and Toxicity study:
All animal experiments were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Louisville. Fifty healthy female Sprague Dawley
rats (4 weeks old) were purchased from Charles River Laboratories (Wilmington, MA).
Rats were fed a standard chow diet and water for the entire duration of the experiment. At
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6 week ages, blood samples were collected from the saphenous vein of all animals to be
used as a baseline control. On day 2, the animals were randomly divided into 5 groups and
injected through tail vein with GNPs coated with Gd(III)- DO3A-SH and/or thioldeprotected oligonucleotides (AS1411, CRO (an analog of AS1411 with all G’s replaced
with C’s), and CTR (a short sequence of thymidylates), MultiHance (Gadobenate
Dimeglumine Injection), or saline ( MultiHance and saline were used as controls). Rats
were euthanized using CO2 and blood samples were collected through Cardiac Puncture
using 23G one inch syringes after two or fourteen days from each group. Blood samples
were centrifuged (800g) to collect 200 µl of serum for the general health profile chemistry
panel and organs were collected and stored in 10% formalin for ICP-MS analysis.

(a) Inductively Coupled Plasma Mass Spectrometry (ICP-MS):
The sample preparation for ICP-MS/MS analysis consisted of a microwave acid
digestion of the collected tissue. The samples (about 80-200mg) were placed into 10 ml
Pyrex digestion vials, 2 ml of concentrated trace metal grade nitric acid was added, and
samples were kept at room temperature for 2 hours as pre-digestion step. Then 0.5 ml of
1:1 hydrochloric acid and 20 ml of internal standard solution containing Indium was added
and the closed vials were microwaved in a CEM Discovery digestion system. The
temperature program consisted on a 10 minute ramp to 110 °C with one minute holding
followed by a 10 minute ramp to 195 °C with a 15 minutes holding time. The maximum
pressure was set at 295 PSI and the maximum power of 300 Watts.
Once the digestion was completed the samples were brought to a final volume of
20 ml with doubly deionized water for a final concentration of 10 ppb of the internal
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standard before the analysis.
The total element analysis was carried out using an Agilent ICP-MS/MS system. It
consisted on a SPS 4 Autosampler, a micromist quartz nebulizer, a Double pass Scott spray
chamber cooled to 2°C, a 2.5 mm ID standard torch, nickel sampler and skimmer cones.
The quantification was performed by the external calibration method with gold and
gadolinium standards in the 0.5 to 200 ppb range with Indium used as internal standard at
a concentration of 10 ppb. For the calibration, R values of 0.9990 or larger and blank
equivalent concentration lower than 50 ppt were obtained for both elements.
The analysis was performed for the following isotopes: 197Au, 157Gd and 155In. The
integration time per isotope was set at 0.1 s, and the probe rinsing program consisted on a
10% nitric acid followed by 5% HCl solutions.

(b) General Health Profile Chemistry Analysis:
Blood chemistry analysis (General Health Profile) was performed on 50 Sprague
Dawley (Crl:SD) rats. Blood was taken before treatment exposure and after (day 2 and day
14) after euthanasia. The GHP was performed at U of L through Research Resource Center
(RRC) and detects the following: alkaline phosphate (ALP), alanine transaminase (ALT),
creatinine (CREA), total bilirubin (TBIL), and blood urea nitrogen (BUN).
For the baseline measurements (before treatment), the blood volume taken from the
rats (6 weeks old) was 100ul for each rat through the saphenous vein. After blood
collection, the blood was centrifuged to collect 40 µl of serum which was needed for the
GHP analysis (minimum detection limit). After euthanasia (day 2 or 14), blood collection
was performed through the heart’s atrium yielding around 1 ml. This allowed for a higher
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volume of serum (200 µl) to be collected and analyzed through the GHP.

2.16 Statistical Analysis:
For blood chemistry results, we performed two statistical tests to analyze the data
that were collected. The first test is based on using unpaired t-test by assuming all the
involved biomarkers in this experiment are independent. The second statistical test is based
on using ANOVA test in order to make group analysis in case the collected biomarkers are
dependent/correlated. For both tests we calculated the p-value to determine if there is the
significant change in the measured biomarkers that they may related to the toxic effect of
the particles. Differences in data were considered significant if p values…less than 0.05.
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CHAPTER 3: RESULTS AND DISCUSSION

3.1 Characterization of solutions of GNP and GNP Gd(III)DO3A-SH Oligonucleotide:
Dynamic light scattering (DLS) was measured to determine the size distribution
profile of the particles and hydrodynamic size in solutions of GNP and GNP Gd(III)DO3ASH oligonucleotide. Transmission electron microscopy (TEM) was used to determine the
size of gold nanoparticles GNP and GNP Gd(III)DO3A-SH oligonucleotide. Zeta Potential
were measured to determine particles stability for solutions of citrate capped GNP and
GNP Gd(III)DO3A-SH oligonucleotide.

Table 1: DLS, TEM, Zeta Potential characterization of citrate capped GNP and GNP
Gd(III) DO3A-SH Oligonucleotide.
Sample
GNP Gd(III)
DO3A-SH AS1411
GNP Gd(III)
DO3A-SH CRO
GNP Gd(III)
DO3A-SH CTR
GNP Citrate

Hydrodynamic size (nm) TEM (nm)
13.5 ± 2.1
3.4 ±0.6

Zeta Potential (mV)
-20.9 ± 1.1

19.3 ± 2.5

3.3 ± 0.6

-57.6 ±1.0

9.83 ± 1.45

5.45 ± 1.42

-42.67 ±4.15

4.88 ± 0.51

4.0 ± 0.7

-16.25 ± 2.30

Table 1 shows that the compact monomeric quadruplex formation of AS1411 leads
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to the relatively smaller hydrodynamic diameter of GNP-Gd(III)-DO3A-SH-AS1411 (13.5
± 2.1) in comparison to GNP-Gd(III)-DO3A-SH-CRO (19.3 ± 2.5). A zeta (ζ) potential of
-(58 – 20) mV was observed for GNP Gd(III)DO3A-SH Oligonucleotide solutions, which
displayed high stability and resistance to aggregation in PBS dispersions. On the other
hand, the citrate capped gold nanoparticles (GNP) aggregated in PBS dispersions and
therefore zeta (ζ) potential and hydrodynamic size characterizations were performed in
nanopure water.

Figure 6: TEM image and particle size histogram for GNP-Gd-DO3A-SH-AS1411
(n=500)

Figure 7: TEM image and particle size histogram for GNP-Gd-DO3A-SH-CRO (n=500)
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Figure 8: TEM image and particle size histogram for GNP-Gd-DO3A-SH-CTR (n=500)
Figures 6-8 show that TEM images of GNP-Gd(III)DO3A-SH-Oligonucleotide
(AS1411/CRO/CTR) reveal average gold core diameters of (3-6) nm. Although the
particles are coated with aptamer and contrast agent, only the gold core of the particles is
electron dense enough to have contrast in this imaging technique using formvar coated
sample grids. TEM characterizations were performed in nanopure water. Citrate-capped
GNP and GNP-Gd(III)DO3A-SH Oligonucleotide solutions were stable for more than 6
months in solution at 4ºC and 37ºC, respectively based on UV-vis measurement.

3.2. Oligonucleotides Determination and quantification:
(a) OliGreen Fluorescence and Darkfield microscopy:
As demonstrated in table 2, three samples solution were stained with OliGreen dye.
GNP Gd(III) DO3A-SH, 1 X PBS Buffer, and GNP Gd(III) DO3A-SH AS1411 to
determine the presence of oligo in the samples. The test solution (GNP Gd(III) DO3A-SH
AS1411) has a higher reading (3988.6 FLU) in comparison to GNP Gd(III) DO3A-SH
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Table 2: OliGreen staining fluorescence values (FL) obtained for GNP Samples using
Blue Module (Excitation 460 nm; Emission 515-570 nm).
Samples
GNP Gd(III) DO3A-SH AS1411
GNP Gd(III) DO3A-SH
1 X PBS Buffer

Fluorescence (FLU)
3988.6
37.5
74.6

OliGreen tagged GNP-Gd(III) DO3A-SH-AS1411, GNP-Gd(III)-DO3A-SH, and
non-OliGreen tagged GNP-AS1411 were imaged using dark field fluorescence microscopy
(see figure 9). The left side of the figure demonstrates gold nanoparticles images. While
the right sides demonstrates OliGreen-tagged particles.

Figure 9: Darkfield (Left) and Fluorescence (Right) characterization of OliGreen tagged
GNP-Gd(III) DO3A-SH-AS1411(Top), GNP-Gd(III)-DO3A-SH (middle) and nonOliGreen tagged GNP-AS1411 (Bottom).
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(b) UV-visible Absorption Spectra Method:
The concentration of oligonucleotides (max = 280 nm) and gold nanoparticles (max
= 530 nm) were calculated using Beer’s Law equation (A= e L c; A is the absorbance, e is
the molar extinction coefficient,(extinction coefficient values: 3620000, 323500, 268800,
49200 L(mole.cm) for 4nm gold nanoparticles, AS1411, CRO, CTR respectively), L is the
path of length of the cell holder, and c is the concentration)[20][21]. Then the number of
oligonucleotides per gold nanoparticle was calculated by dividing the concentration of
oligonucleotides by the concentration of gold nanoparticles.

Table 3: Number of oligonucleotides per gold nanoparticles for two aliquots.
Sample
GNP Gd(III) DO3A-SH AS1411
GNP Gd(III) DO3A-SH CRO

Quantification of Oligonucleotides
10 ± 2
9±2

3.2 Gadolinium quantification:
Gadolinium and gold were quantified using Energy Dispersive X-Ray Analysis
(EDAX). The sample is bombarded with an electron beam, which leads to electron transfer.
The transferring electrons must give up some of their energy by emitting an X-ray. Each
atom of every element releases a unique amount of X-ray during electron transferring
process.
An EDX spectrum demonstrates peaks corresponding to the energy levels for which
the most X-rays had been received. Each of these peaks is unique to an atom, and therefore
corresponds to a single element. The higher a peak in a spectrum, the more concentrated
the element is in the specimen.
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Figure 10: Energy Dispersive X-Ray Spectrum of GNP Gd(III) DO3A-SH AS1411

Figure 11: Energy Dispersive X-Ray Spectrum of GNP-Gd(III)DO3A-SH-CRO
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Figure 12: Energy Dispersive X-Ray Spectrum of GNP-Gd(III)DO3A-SH-CTR
Figures 10-12 demonstrate the quantification of gadolinium using Energy
Dispersive X-ray Assay (EDAX), the spectrum of three samples GNP-Gd(III)DO3A-SHAS1411, GNP-Gd(III)DO3A-SH-CRO, and GNP-Gd(III)DO3A-SH-CTR. X-ray counts
were plotted vs. energy (in keV). Energy peaks coincide with the various elements in each
sample.
Table 4: Atomic and Weight percentages of elements analyzed in Energy Dispersive XRay Analysis of GNP Gd(III) DO3A-SH AS141.
Element
CK
OK
NaK
AuM
ClK
KK
GdL

Wt. %
21.34
16
27.57
15.06
14.95
2.88
2.21
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At %
38.95
21.93
26.29
1.68
9.24
1.61
0.31

Table 5: Atomic and Weight percentages of elements analyzed in Energy Dispersive XRay Analysis of GNP-Gd(III)DO3A-SH-CRO

Element
CK
OK
NaK
MgK
ClK
KK
GdL
AuL

Wt.%
At%
27.13
52.39
22.84
33.11
8.04
8.11
0.62
0.59
0.89
0.58
0.67
0.4
4.02
0.59
35.78
4.21

Table 6: Atomic and Weight percentages of elements analyzed in Energy Dispersive XRay Analysis of GNP-Gd(III)DO3A-SH-CTR
Element

Wt. %

At %

CK
SiK

7.85
15.6

40.77
34.64

AuM
GdL

71.99
4.55

22.79
1.8

Tables 4-6 show the atomic and weight percentages of elements in each sample.
The atomic and weight percentages of Au and Gd per each gold particles are calculated for
GNP-Gd(III)DO3A-SH-As1411, GNP-Gd(III)DO3A-SH-CRO, GNP-Gd(III)DO3A-SHCTR solutions.

3.3 MRI Phantom:
To evaluate contrast enhancement by GNP–Gd(III)DO3A-SH-Oligonucleotide, the
longitudinal T1 relaxation and T1-Weighted measurements were made at nanomolar GNP
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concentrations (1200, 300, 75 nM) and compared with GNP-SH-Oligonucleotides as a
control (figure 13)

Figure 13: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH
Oligonucleotide.

The % Relaxivity enhancement was calculated as described in the method section.
As demonstrated in Figure 10, as we increase the concentration of GNP–Gd(III)DO3A-SHOligonucleotide there is increase in the percentage of relaxivity enhancement.

3.4 In vitro imaging results:
To evaluate the selective targeting induced contrast enhancement by GNP–
Gd(III)DO3A-SH-Oligonucleotide, the longitudinal T1 relaxation and T1-Weighted
measurements were made at nanomolar GNP concentrations (1200, 300, 75 nM) and
compared with corresponding clinically relevant Multihance concentrations (1700, 7000,
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27900 nM) in breast cancer cells (MDA-MB-231) and non-malignant breast epithelial cells
(MCF-10A). For control experiments with MultiHance, the concentrations (1700, 7000,
27900 nM) were obtained by quantifying the Gd content per GNP using Energy Dispersive
X-Ray (EDAX) analysis procedures (17, 18). The atomic ratios of Gd:Au were
subsequently measured to quantify Gd content per GNP. MRI scans were applied to the
treated cells after incubation for four time intervals (24, 48, 72, and 96).

Table 7: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH
Oligonucleotide in MDA-MB-231 & MCF-10A cell lines using T1-Weighted image
analysis algorithm, * A = AS1411, B = CRO, C = CTR, ** M = MultiHance
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Figure 14: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH
Oligonucleotide in MCF-10A cell line using T1-Weighted image analysis algorithm after
24 hours.

Figure 15: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH
Oligonucleotides in MCF-10A cell line using T1-Weighted image analysis algorithm
after 48 hour.
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Figure 16: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH
Oligonucleotide in MCF-10A cell line using T1-Weighted image analysis algorithm after
72 hours.

Figure 17: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH
Oligonucleotide in MCF-10A cell line using T1-Weighted image analysis algorithm after
96 hours.
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Figure 18: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH
Oligonucleotide in MDA-MB-231 cell line using T1-Weighted image analysis algorithm
after 24 hours.

Figure 19: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH
Oligonucleotide in MDA-MB-231 cell line using T1-Weighted image analysis algorithm
after 48 hours.
34

Figure 20: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH
Oligonucleotide in MDA-MB-231 cell line using T1-Weighted image analysis algorithm
after 72 hours.

Figure 21: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH
Oligonucleotide in MDA-MB-231 cell line using T1-Weighted image analysis algorithm
after 96 hours.
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As demonstrated in table 7 and figures 14-21 the enhancement of MRI relaxivity
using GNP Gd(III)DO3A-SH Oligonucleotide is higher for MDA-MB-231 images than
MCF-10A images upon the selective accumulation in cancer cells. MRI images were
analyzed using T1-Weighted image analysis algorithm (as described in the methods
section), Samples of GNP–Gd(III)DO3A-SH-AS1411/CRO display significantly higher
relaxivity values compared to GNP–Gd(III)DO3A-SH-CTR at 24 hours. While GNP–
Gd(III)DO3A-SH-AS1411 displays the highest enhancement of relaxivity values at 48, 72,
96 hours upon selective targeting (and retention inside) of cancer cells upon binding with
nucleolin protein which is highly expressed in the cytoplasm and cell surface (highest
enhancement achieves at 72 hours).

3.4 In Vivo Biodistribution Study:
(a) Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Results:
The biodistribution of gold nanoparticles in seven organs (brain, heart, lung, large
intestine, kidney, spleen, and liver) had been investigated by ICP-MS. Seven organs were
collected after the injection of the five treatment groups by 2 or 14 days.

Figure 22: Uptake and biodistribution of gold in different body organs.
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 To simplify the figures, CTR stands for GNP Gd (lll) DO3A-SH CTR, CRO
stands for GNP Gd (lll) DO3A-SH CRO, and AS1411 stands for GNP Gd (lll)
DO3A-SH AS1411.
ICP-MS results show the biodistribution of gold nanoparticles in seven organs
(brain, heart, lung, large intestine, kidney, spleen, and liver) of 50 rats after injection with
GNP–Gd(III)DO3A-SH- oligonucleotides, saline, and MultiHance. Animals were
sacrificed after 2 and 14 days of injections. The liver and spleen show the highest
concentration of gold nanoparticles with respect to other organs. Moreover, the
concentrations of the particles on day 14 are less than the concentrations in day 2 for both
organs, suggesting ongoing clearance of nanoparticles from these organs.

(b) Blood Chemistry Analysis:
Blood samples were drawn from the rats after treatment with GNP Gd (lll) DO3ASH AS1411, GNP Gd (lll) DO3A-SH CRO, GNP Gd (lll) DO3A-SH CTR, MultiHance,
and Saline for blood analysis at 2 time points (2 or 14 day). Five blood biomarkers (BUN,
ALT, ALKP, CREA, and TBIL) were chosen to evaluate liver and kidney functions.
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Figure 23: BUN post-treatment blood concentrations of 5 treatment groups.

Figure 24: CREA post-treatment blood concentrations of 5 treatment groups

Figure 25: ALT post-treatment blood concentrations of 5 treatment groups.
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Figure 26: ALKP post-treatment blood concentrations of 5 treatment groups.

Figure 27: TBIL post-treatment blood concentrations of 5 treatment groups.

 To simplify the figures, CTR stands for GNP Gd (lll) DO3A-SH CTR, CRO
stands for GNP Gd (lll) DO3A-SH CRO, and AS1411 stands for GNP Gd (lll)
DO3A-SH AS1411.
As demonstrated in figures 23-27 the post-treatment blood levels of BUN (mg/dL),
CREA (mg/dL), ALT (U/L), ALKP (U/L), and TBIL (mg/dL) were plotted for the five
different treatment groups at day 2 and day 14.
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(c) Statistical Analysis:
We performed two statistical tests on the blood chemistry results to analyze the data
that were collected. The first test is based on using unpaired t-tests by assuming all the
involved biomarkers in this experiment are independent. The second statistical test is based
on using ANOVA test in order to make a group analysis in case the collected biomarkers
are dependent/correlated.
First, post-treatment blood biomarkers BUN, CREA, ALT, ALKP, and TBIL
values were analyzed by using unpaired T test, Tables 8 and 9. The blood biomarkers for
each group (MultiHance, GNP Gd (lll) DO3A-SH CTR, GNP Gd (lll) DO3A-SH CRO,
GNP Gd (lll) DO3A-SH As1411) were compared with blood biomarkers for a saline control
group at days 2 and 14 respectively. As demonstrated in Table 8, the statistical results show
that all of the variables do not have a significant difference between GNP Gd (lll) DOA3SH AS1411 and control group at day 2. However, the unpaired t-test detects significant
differences occur for BUN and CREA biomarkers for the following post-treatment agents:
MultiHance, GNP Gd (lll) DOA3-CTR, and Gd (lll) DOA3-CRO as demonstrated by bold
highlighted values in Table 8. In a similar way, Table 9 shows the estimated P-values by
day 14. It is clear that there are no significant differences between biomarkers blood levels
of the animals injected with test solution GNP Gd(III)-DO3A-SH-AS1411 and biomarkers
blood levels of the animals injected with saline solution.
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Table 8: P-values of unpaired T test for day 2 post-treatment
Blood
Biomarker

Saline &
MultiHance

BUN
CREA
ALT

0.0078
1.000
0.1605

Saline & GNP
Gd (lll) DO3ASH CTR
0.0085
1.000
0.1605

ALKP
TBIL

0.0565
1.000

0.0565
1.000

Saline & GNP
Gd (lll) DO3ASH CRO
0.0073
0.0278
0.0795BUN,
CREA
0.7108
0.8836

Saline & GNP
Gd (lll) DO3ASH AS1411
0.3322
1.000
0.2196
0.0515
0.6305

Table 9: P-values of unpaired T test for day 14 post-treatment:
Blood
Biomarker

Saline &
MultiHance

Saline & GNP
Gd (lll) DO3ASH CTR

Saline & GNP
Gd (lll) DO3ASH CRO

BUN
CREA
ALT
ALKP
TBIL

0.4482
1.000
0.4253
0.8178
1.000

0.9152
1.000
0.1713
0.5414
0.1525

0.9256
1.000
0.6656
0.3824
0.6317

Saline &
GNP Gd (lll)
DO3A-SH
AS1411
0.2155
Perfect data
0.0844
0.9619
1.000

For more investigation, we performed an ANOVA test in case there are correlations
between the measured biomarkers. In this statistical test, we used a factorial design with
post- treatment interval (2 days or 14 days) and treatment agents, along with their
interaction effect. The dependent variables were the log-transformed post-treatment
biomarkers relative to control: in (BUNTest / BUNControl), etc. The linear model was fit
to each biomarker independently. The ANOVA was performed to test whether there was
any significant treatment agent-dependence on the change in biomarker levels. The results
show that the BUN, ALT, ALKP, and TBIL data were not significantly different from our
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null hypothesis that there is a significant treatment agent-dependence on the change in
biomarker levels (χ2 = 15.2, 12.3, 12.5, 9.45 respectively, with 9 degrees of freedom [d.f.];
p = 0.08, 0.20, 0.19, and 0.051 respectively).
Both statistical tests (unpaired t-tests and ANOVA) demonstrate that there are no
significant difference in post-treatment blood levels of BUN, ALT, CREA, ALKP, and
TBIL between GNP Gd (lll) DOA3-SH AS1411 and saline group, which means the
proposed contrast agent (Gd (lll) DOA3-SH AS1411) does not affect liver and kidney
functions and it is safe for animals.
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CHAPTER 4: CONCLUSIONS

We have developed cancer-targeted gold nanoparticle-based MRI contrast agent
consisting of: a 4 nm diameter gold nanoparticle, cancer targeting DNA aptamer (AS1411),
and a gadolinium chelate contrast agent (Gd(III)-DO3A-SH). The particles were
characterized using DLS, UV-vis, and TEM. Zeta potential for GNP Gd (lll) DOA3-SH
AS1411 was -20.9 ± 1.1 which, displayed high stability. The selective targeting ability was
evaluated by in-vitro study using MDA-MB-231 and MCF-10A cell lines. AS1411 is
included in the coating to allow the nanoparticles to be selectively retained in cancer cells
upon binding to nucleolin protein, which is expressed on the cell surface and in the
cytoplasm of cancer cells. Since nucleolin is found solely in the nucleus of healthy cells,
where it is unavailable for binding to our nanoparticles, AS1411-coated particles are not
retained in healthy cells.
Oligonucleotide anchoring to the nanoparticle surface, along with steric crowding
within the corona monolayer, slows the rotational tumbling rate of the Gd3+ chelate and
therefore reduces the T1 relaxation time, hence increasing the T1-Weighted image contrast
of GNP–Gd(III)DO3A-SH-Oligonucleotide. The local voxel wise and global image
analysis of T1- Weighted algorithm on GNP–Gd(III)DO3A-SH-Oligonucleotide construct
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has shown exceptional contrast enhancement for MDA-MD-231 cells targeted by the
cancer specific contrast agent GNP-Gd(III)DO3A-SH-AS1411 compared to its nontargeted control counterparts GNP-Gd(III)-DO3A-SH-CRO/CTR. The nucleolin binding
ability of AS1411 oligonucleotide has led to selective accumulation of gadolinium-based
contrast agent (GBCA) in cancer cells (MDA-MB-231) accomplishing superior contrast
enhancement over non-malignant breast epithelial cells (MCF-10A). Moreover, the T1Weighted image analysis algorithm features steric bulk-induced longitudinal changes by
yielding significantly higher T1-Weighted image for GBCA with longer sequence
oligonucleotides (AS1411/CRO) in comparison to their shorter sequence counterpart CTR,
particularly in the breast cancer cells. All of these studies suggest that GNP-Gd(III)DO3ASH-AS1411 has the potential use of enabling discrimination between cancerous and
healthy tissue using MRI.
Our in-vivo toxicity and biodistribution study shows that the proposed contrast
agent GNP (Gd(III)-DO3A-SH-AS1411 is not toxic for healthy rats. ICP-MS analysis
demonstrates that the particles were cleared from all body organs Although there are
elevated levels of GNP-Gd(III)DO3A-SH-AS1411 in the liver and spleen, the
concentrations of the particles on day 14 are less than the concentrations in day 2 for both
organs, suggesting ongoing clearance of nanoparticles from these organs.
We selected five blood biomarkers to evaluate the toxicity of the contrast agent.
BUN and CREA were used to evaluate kidney function and ALT, TBIL, and ALKP were
used to evaluate liver function. Our statistical analysis results show that there is not any
significant difference between biomarkers blood levels of the animals injected with test
solution GNP Gd(III)-DO3A-SH-AS1411 and biomarkers blood levels of the animals
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injected with saline solution.
Our proposed cancer-targeted contrast agent (GNP (Gd(III)-DO3A-SH-AS1411) exhibits
MRI contrast with higher relaxivity in cancer cells in comparison to normal cells by in vitro
study ,and the particles were not toxic for healthy animals. The evidence thus far suggests
that GNP-Gd(III)DO3A-SH-AS1411 is worth investigating further both in vitro and in vivo
to optimize cancer targeting and contrast capabilities.
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